ArticleBMC infectious diseases2019
Outbreak of macrolide-resistant mycoplasma pneumoniae in a primary school in Beijing, China in 2018.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a meta-analysis.Italian journal of pediatrics · 2022Pooled it
- Urban environmental and climatic correlates of pediatric respiratory infection: microscale spatiotemporal evidence from Fuzhou, China.BMC pediatrics · 2026Article
- In the shadow of COVID-19: changes in the seroprevalence of pediatric Mycoplasma pneumoniae.BMC infectious diseases · 2026Article
- Epidemiological association of the COVID-19 pandemic onBMJ open · 2025Article
- Mycoplasma pneumoniae detections in children with acute respiratory infection, 2010-2023: a large sample study in China.Italian journal of pediatrics · 2025Article
- Evaluating the effectiveness of different intervention measures for an outbreak of mycoplasma pneumoniae in hangzhou based on a dynamic model.Scientific reports · 2025Article
- Risk factors and prescription patterns analysis for macrolide-resistant Mycoplasma pneumoniae pneumonia in children.iScience · 2024Article
- Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World journal of pediatrics : WJP · 2024Review
- Mycoplasma pneumoniae detections in children with lower respiratory infection before and during the COVID-19 pandemic: a large sample study in China from 2019 to 2022.BMC infectious diseases · 2024Article
- De ja vu? Post-COVID-19 Surge in Respiratory Illnesses Among Children in China Emphasizes Need for Proactive Surveillance, Openness, Early Detection and Reporting of Causative Pathogen(s), and Their AMR Status.Journal of epidemiology and global health · 2024Article
- Influence of COVID-19 pandemic on the epidemiology ofHeliyon · 2023Article
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- Article
- The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic.Frontiers in cellular and infection microbiology · 2022Article
- Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China.BMC pediatrics · 2021Article
- Emergence of Macrolide-ResistantPathogens (Basel, Switzerland) · 2021Article
- Dynamic change ofTranslational pediatrics · 2020Article
- Molecular Detection and Evaluation of MLـ ResistanceReports of biochemistry & molecular biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOn 7th June, 2018, a primary school in Beijing, China notified Shunyi CDC of an outbreak of acute respiratory disease characterized by fever and cough among students and resulting in nine hospitalization cases during the preceding 2 weeks. We started an investigation to identify the etiologic agent, find additional cases, develop and implement control measures.
methodsWe defined probable cases as students, teachers and other staffs in the school developed fever (T ≥ 37.5 °C) with cough or sore throat; or a diagnosis of pneumonia during May 1-June 31, 2018. Confirmed cases were probable cases with Mycoplasma pneumoniae detected in oropharyngeal (OP) swabs by quantitative real-time polymerase chain reaction (qPCR). We searched case by reviewing school absenteeism records and interviewing students, teachers and staff in this school. Oropharyngeal swabs were collected from symptomatic students. Two qPCR) assay, a duplex qPCR assay, and sequencing were performed to determine the pathogen, genotype and macrolide resistance at the gene level, respectively.
resultsFrom May 1st to June 31st, 2018, we identified 55 cases (36 probable and 19 confirmed), of whom 25 (45%) were hospitalized for complications. All cases were students, none of the teachers and other staffs in the school were with similar symptoms. The attack rate (AR) was 3.9% (55/1398) for all students. The cases were mainly male (58%), with an age range of 7-8 years (median: 7 years). 72% (18/25) of inpatients had radiograph findings consistent with pneumonia, and some cases were hospitalized for up to 4 weeks. Pathogen detection results indicated that Mycoplasma pneumonia (M. pneumoniae) P1 type 1 was the causative agent in this outbreak, and the strain harbored one point mutation of A to G at position 2063.
conclusionsThe infections by macrolide-resistant M. pneumoniae are not always mild and pneumonia was common and M. pneumoniae could causes serious complications which require long-term hospitalization. In the future infectious disease prevention and control practice, M. pneumoniae should be paid more attention. It is necessary to establish and improve the pathogen and drug resistance surveillance system in order to prevent and control such mutated strains of M. pneumoniae from causing future outbreaks or epidemics in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.